Si-Based Agent for Pharmaceuticals, Health, and Well-Being
Prof. Hikaru Kobayashi — Professor Emeritus @ The University of Osaka
Prof. Hikaru Kobayashi presents a novel silicon-based agent designed to combat oxidative
"By administration of silicon waste agent, it is expected that many diseases can be treated or prevented by decreasing oxidative stress, potentially preventing and treating diseases and retarding aging."
Summary
- Developed silicon-based agent reacts with intestinal water to generate hydrogen for 24 hours, reducing harmful OH radicals linked to diseases and aging. - OH radicals cause oxidative stress, promoting diseases like diabetes, Parkinson's, and chronic kidney disease; silicon agent may prevent these. - Silicon agent produces hydrogen only in intestines (pH ~8.3), not in stomach acid, enabling continuous hydrogen release and absorption. - Administration reduces OH radical levels significantly, possibly via glutathione persulfide formation, which neutralizes radicals effectively. - Animal and human cases show improvements in atopic dermatitis, diabetes, hair loss, aging symptoms, and potential benefits for Alzheimer's disease.
Article
Silicon-based agent shows promise in neutralising oxidative stress and combating age-related disease
Revolutionary hydrogen-generating compound demonstrates therapeutic potential across range of conditions, from diabetes to Alzheimer's
Tokyo research unveils novel approach to eliminating harmful radicals linked to chronic illness and ageing
Breakthrough in oxidative stress reduction
Professor Hikaru Kobayashi presented groundbreaking research on a silicon-based pharmaceutical agent at the Hololife Summit 2025 Tokyo, revealing a novel approach to combating oxidative stress through continuous hydrogen generation within the human intestine. The research, supported by animal studies from Osaka University's Graduate School of Medicine, demonstrated remarkable therapeutic potential across a spectrum of conditions ranging from chronic kidney disease to Alzheimer's.
The silicon-based agent operates through a deceptively simple mechanism: upon contact with intestinal fluids at pH 8.3 to 8.5, it reacts with water to generate hydrogen continuously over a 24-hour period. This sustained release represents a significant advancement over traditional hydrogen-rich water, as one gram of the agent produces hydrogen equivalent to 25 litres of saturated hydrogen water—an impractical volume for daily consumption.
"Large amounts of hydrogen are generated continuously in the intestines, equivalent to what is contained in 25 liters of hydrogen-rich water, but by simply taking one gram of silicon waste agent," Kobayashi explained during the presentation.
Targeting the root of oxidative damage
The research addresses a fundamental challenge in medical science: the elimination of hydroxyl (OH) radicals, among the most destructive reactive oxygen species produced during normal metabolism. These radicals possess exceptional oxidative power, damaging cellular structures and contributing to numerous diseases including diabetes, Parkinson's disease, chronic renal failure, and accelerated ageing.
Current medical approaches lack effective methods for neutralising these constantly-generated radicals. Kobayashi's team discovered that whilst hydrogen molecules themselves bond too strongly to react directly with OH radicals, the silicon agent facilitates a more sophisticated mechanism. The agent increases production of glutathione persulfide, a powerful reducing agent that effectively scavenges OH radicals throughout the body.
"Oxidative stress exceeds the body's repair function, leading to illness; by reducing oxidative stress, the silicon waste agent helps keep risk factors below the repair threshold, preventing disease," Kobayashi noted.
Strategic activation in the intestinal environment
A key innovation lies in the agent's selective activation. The compound remains inert in the acidic stomach environment (pH below 4), preventing premature reaction. Only upon reaching the intestines, where pancreatic and intestinal secretions create an alkaline environment of pH 8.3 to 8.5, does hydrogen generation commence.
This strategic activation ensures optimal absorption whilst eliminating potential adverse effects. Notably, the silicon-based agent itself is not absorbed into the bloodstream—only the generated hydrogen enters systemic circulation. This characteristic has contributed to the absence of observed adverse effects in studies conducted to date.
Experimental verification demonstrated that the agent generates approximately 1.5 litres of hydrogen over 24 hours when exposed to conditions mimicking intestinal fluids (pH 8.3, 36°C). Video documentation showed continuous bubble formation from the black silicon compound, confirming sustained hydrogen production throughout the test period.
Clinical observations demonstrate therapeutic potential
Perhaps most compelling were the clinical cases presented, spanning both veterinary and human subjects. A 15-year-old dog unable to walk properly regained mobility after one month of treatment, suggesting anti-ageing effects. Multiple cases of atopic dermatitis in dogs showed complete resolution of hair loss and skin inflammation within two to eight weeks.
A diabetic cat with blood sugar levels double the normal range returned to healthy levels after 40 days of administration, accompanied by significant hair regrowth. Human cases proved equally dramatic: a patient suffering from atopic dermatitis for over a decade, unresponsive to conventional ointments, experienced near-complete symptom resolution after three weeks. A hairdresser with severe contact dermatitis saw improvement within five days and near-complete healing by day ten.
Evidence of OH radical elimination
Kobayashi's team developed a laser-based detection method to measure minute quantities of OH radicals emitted from human palms. In a self-administered trial using 200mg daily doses, initial high levels of OH radicals decreased progressively, becoming nearly undetectable by day 13. Upon cessation of the agent, OH radical levels returned to baseline, confirming the compound's direct effect on oxidative stress.
The proposed mechanism involves hydrogen atoms weakly bonded to the silicon agent's surface being captured by glutathione to form glutathione persulfide. This high-reducing-power compound can then be transported throughout the body, donating hydrogen atoms to neutralise OH radicals by forming water.
Implications for major disease categories
Animal experiments conducted at Osaka University revealed significant therapeutic effects across conditions affecting millions. In Japan alone, chronic renal failure affects 13 million patients, diabetes 10 million, and atopic dermatitis another 10 million. Recent findings also suggested high efficacy against Alzheimer's disease, a condition of increasing prevalence in ageing populations.
The research positioned oxidative stress as a common denominator across diverse pathologies. By reducing oxidative stress below the threshold of the body's natural repair mechanisms, the silicon-based agent may prevent disease development even when other risk factors remain present.
"Hydrogen molecules are very tightly bonded, making direct reactions with OH radicals unlikely, but glutathione persulfide, increased by silicon waste agent, has high reducing power to eliminate OH radicals," Kobayashi explained, highlighting the sophisticated biochemical pathway involved.
Future directions and broader applications
The presentation concluded with a comprehensive summary chart of oxidative stress-induced diseases, marking those conditions for which the silicon-based agent demonstrated high medical effectiveness in Osaka University animal experiments. Beyond disease treatment, the agent showed potential for retarding ageing processes, as evidenced by mobility restoration in elderly animals and hair regrowth across multiple species.
The research represents a convergence of materials science, biochemistry, and clinical medicine. By creating a compound that generates therapeutic hydrogen precisely where it can be most effectively absorbed, Kobayashi's team has developed a platform technology with potential applications spanning numerous chronic conditions united by oxidative stress mechanisms.
As global populations age and chronic disease burden increases, interventions targeting fundamental pathological processes rather than individual symptoms may prove transformative. The silicon-based agent's ability to address oxidative stress—a common thread across diverse pathologies—positions it as a potentially significant advancement in preventive and therapeutic medicine.
The simplicity of administration, absence of observed adverse effects, and breadth of therapeutic potential suggest this approach warrants continued investigation through rigorous clinical trials. Should larger studies confirm these preliminary findings, silicon-based hydrogen generation may become a cornerstone strategy for managing oxidative stress-related conditions and promoting healthy ageing.
Part of Hololife Summit 2025 Tokyo